Over the past 12 months, 7 insiders at Janux Therapeutics, Inc. filed 12 open-market SEC Form 4 transactions on JANX: 0 purchases worth $0 and 12 sales worth $1.1M. Insiders have been net sellers over this period. The most recent filing was on Jun 2, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 26 | Janeen Noel DoyleChief Corp. & Bus. Dev. Ofcr | SELL | 4.1K | $14.03 | $57K |
| May 11, 26 | Maria DobekVice President, Accounting | SELL | 2.0K | $14.17 | $29K |
| Jan 2, 26 | David Alan CampbellPresident and CEO | SELL | 8.1K | $13.73 | $111K |
| Jan 2, 26 | Thomas DiraimondoChief Scientific Officer | SELL | 2.5K | $13.73 | $34K |
| Jan 2, 26 | Maria DobekVice President, Accounting | SELL | 1.5K | $13.73 | $20K |
| Jan 2, 26 | Zachariah McIverChief Medical Officer | SELL | 2.7K | $13.73 | $37K |
| Jan 2, 26 | Andrew Hollman MeyerChief Business Officer | SELL | 1.9K | $13.73 | $26K |
| Jan 2, 26 | Charles M. WinterChief Technical Officer | SELL | 2.4K | $13.73 | $33K |
| Dec 1, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 2.7K | $33.52 | $89K |
| Nov 14, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 3.3K | $30.00 | $100K |
| Oct 28, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 16.7K | $30.06 | $501K |
| May 1, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 2.9K | $32.60 | $94K |
| Apr 21, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 3.3K | $30.00 | $100K |
| Mar 7, 25 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | BUY | 110.2K | $31.02 | $3.4M |
| Mar 6, 25 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | BUY | 372.1K | $30.78 | $11.5M |
| Mar 5, 25 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | BUY | 304.3K | $31.30 | $9.3M |
| Mar 3, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 2.4K | $32.85 | $78K |
| Feb 3, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 2.4K | $43.60 | $102K |
| Jan 7, 25 | David Alan CampbellPresident and CEO | SELL | 5.0K | $60.00 | $300K |
| Jan 2, 25 | Andrew Hollman MeyerChief Business Officer | SELL | 5.8K | $57.37 | $314K |
| Dec 24, 24 | David Alan CampbellPresident and CEO | SELL | 25.0K | $56.19 | $1.4M |
| Dec 3, 24 | David Alan CampbellPresident and CEO | SELL | 15.0K | $67.00 | $1.0M |
| Nov 25, 24 | David Alan CampbellPresident and CEO | SELL | 18.3K | $52.04 | $940K |
| Oct 28, 24 | David Alan CampbellPresident and CEO | SELL | 13.9K | $53.94 | $740K |
| Oct 18, 24 | Peter KolchinskyDirector,TenPercentOwner | BUY | 1.20M | $44.75 | $53.7M |
| Oct 18, 24 | L.p. Avalon Bioventures Spv ITenPercentOwner | SELL | 553.2K | $51.18 | $24.8M |
| Oct 17, 24 | L.p. Avalon Bioventures Spv ITenPercentOwner | SELL | 1.8K | $50.02 | $92K |
| Oct 16, 24 | L.p. Avalon Bioventures Spv ITenPercentOwner | SELL | 61.4K | $50.80 | $3.1M |
| Sep 30, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 958 | $46.24 | $44K |
| Sep 27, 24 | David Alan CampbellPresident and CEO | SELL | 19.0K | $47.84 | $874K |
| Sep 27, 24 | Thomas DiraimondoChief Scientific Officer | SELL | 4.3K | $47.22 | $200K |
| Sep 27, 24 | Andrew Hollman MeyerChief Business Officer | SELL | 50.0K | $45.96 | $2.3M |
| Sep 27, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 46.9K | $47.74 | $2.2M |
| Sep 26, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 50.5K | $47.77 | $2.4M |
| Sep 13, 24 | Jay LichterTenPercentOwner | SELL | 3.8K | $46.68 | $178K |
| Sep 12, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 161.4K | $47.00 | $7.6M |
| Sep 10, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 35.0K | $46.66 | $1.6M |
| Sep 9, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 2.2K | $42.33 | $92K |
| Sep 6, 24 | Avalon Bioventures I, LpTenPercentOwner | SELL | 110.6K | $42.00 | $4.6M |
| Jun 3, 24 | Avalon Ventures Xi, L.p.TenPercentOwner | SELL | 691.5K | $54.75 | $37.9M |
| Jun 3, 24 | Jay LichterDirector,TenPercentOwner | SELL | 691.5K | $54.75 | $37.9M |
| Jun 3, 24 | Tighe ReardonActing Chief Financial Officer | SELL | 691.5K | $54.75 | $37.9M |
| Nov 13, 23 | Avalon Ventures Xi, L.p.TenPercentOwner | BUY | 849.9K | $5.87 | $5.0M |
| Nov 13, 23 | Jay LichterDirector,TenPercentOwner | BUY | 849.9K | $5.87 | $5.0M |
| Nov 13, 23 | Tighe ReardonActing Chief Financial Officer | BUY | 849.9K | $5.87 | $5.0M |
| Jul 19, 23 | Ra Capital Nexus Fund Ii, L.p.Director | BUY | 495.0K | $12.46 | $6.2M |
| Dec 29, 21 | Orbimed Genesis Gp LlcDirector | SELL | 36.7K | $20.30 | $745K |
| Dec 29, 21 | Peter A. ThompsonDirector | SELL | 36.7K | $20.30 | $745K |
| Dec 21, 21 | Orbimed Genesis Gp LlcDirector | SELL | 108.3K | $19.00 | $2.1M |
| Dec 21, 21 | Peter A. ThompsonDirector | SELL | 108.3K | $19.00 | $2.1M |
Over the past 12 months, insiders at Janux Therapeutics, Inc. filed 0 open-market purchases worth $0 and 12 sales worth $1.1M on JANX, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 2, 26.
The largest recent open-market JANX insider purchase in our data was $53.7M by Peter Kolchinsky, Director,TenPercentOwner, filed on Oct 18, 24.
7 different insiders at Janux Therapeutics, Inc. filed open-market SEC Form 4 transactions on JANX over the last 12 months.
InsiderTape plots every JANX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Janux Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →